Importantly, there were no cardiovascular adverse events, no clinically significant changes in blood pressure or heart rate, no alterations in thyroid function, no immunogenicity with no anti-AOD-9604 antibodies detected, and no signs of tolerance or receptor desensitization
2013 and re-evaluated in FDA's 2024 PCAC briefing
Contact our practice in Victoria, TX, at (361) 576-9100 to schedule a consultation.
By reducing nicotinamide methylation, supports cellular NAD+ availabilitya critical coenzyme for mitochondrial function, energy metabolism, and cellular repair
Current AOD-9604 peptide research focuses on peptide-mediated signaling pathways and molecular characterization studied in controlled laboratory and in vitro environments
If you are considering B12 injections, here is an honest account of the risks of poor technique and how a clinic avoids them